Back Hepatitis B Hepatitis B Topics HBV Treatment

AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years

Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.

alt

Read more:

AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.

alt

Read more:

AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk

Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B virus (HBV) infection will develop hepatocellular carcinoma, according to findings presented this week at the 64thAASLD Liver Meeting in Washington, DC. Another study, however, found that while entecavir or tenofovir can reduce the risk, people with hepatitis B should continue to undergo regular monitoring for liver cancer, and better predictive models may be needed for Caucasian patients.

alt

Read more:

AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt